Vol. 5 No. 7 (2025)
Reimbursement Reviews

Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris)

decorative image of the issue cover

Published July 28, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses olopatadine hydrochloride and mometasone furoate nasal spray suspension (Ryaltris): 665 mcg olopatadine hydrochloride and 25 mcg mometasone furoate (as monohydrate) per delivered dose.
  • Indication: For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.